RBSH.US Rebus Holdings Inc.

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Oct 11, 2026
0.0001 0.0001
Market cap
USD 3.21K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is RBSH.US undervalued?

Graham number

The Graham number of Rebus Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rebus Holdings Inc. fundamental analysis

No fundamental analysis for Rebus Holdings Inc. yet.

Rebus Holdings Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rebus Holdings Inc.

Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.

Full company profile